Soligenix, Inc. Common Stock (SNGX)

Price$0.83

Value ScoreC

Growth ScoreF

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-44.28%

Price vs S&P 500 (4W)158.80%

VGM Score30.36

Market Capitalization$13.49M

All Metrics

Book Value / Share (Quarterly)$0.29

P/TBV (Annual)10.22x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-47.39%

Cash Flow / Share (Quarterly)$-1.03

Price vs S&P 500 (YTD)-43.02%

Gross Margin (TTM)8.75%

Net Profit Margin (TTM)-1424.53%

EPS (TTM)$-1.97

10-Day Avg Trading Volume38.35M

EPS Excl Extra (TTM)$-1.97

Revenue Growth (5Y)-51.89%

EPS (Annual)$-2.14

ROI (Annual)-209.37%

Gross Margin (Annual)0.00%

Net Profit Margin (5Y Avg)-2277.89%

Cash / Share (Quarterly)$0.57

ROA (Last FY)-119.98%

EBITD / Share (TTM)$-1.68

ROE (5Y Avg)-248.72%

Operating Margin (TTM)-1574.25%

Cash Flow / Share (Annual)$-1.02

P/B Ratio4.37x

P/B Ratio (Quarterly)3.94x

Net Income / Employee (Annual)$-852,300

EV / Revenue (TTM)15.10x

Net Interest Coverage (TTM)-1725.75x

ROA (TTM)-131.93%

EV / EBITDA (TTM)6.17x

EPS Incl Extra (Annual)$-2.14

Current Ratio (Annual)2.39x

Quick Ratio (Quarterly)1.69x

3-Month Avg Trading Volume4.79M

52-Week Price Return-52.60%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.83

P/S Ratio (Annual)113.01x

Asset Turnover (Annual)0.01x

52-Week High$6.23

Operating Margin (5Y Avg)-2540.96%

EPS Excl Extra (Annual)$-2.14

CapEx CAGR (5Y)-10.08%

Tangible BV CAGR (5Y)6.73%

26-Week Price Return-28.35%

Quick Ratio (Annual)2.15x

13-Week Price Return-20.87%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.81x

Enterprise Value$7.46M

Revenue / Share Growth (5Y)-54.25%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)-12.22%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-7267.90%

Cash / Share (Annual)$0.79

3-Month Return Std Dev223.32%

Gross Margin (5Y Avg)17.76%

Net Income / Employee (TTM)$-842,600

ROE (Last FY)-209.37%

Net Interest Coverage (Annual)-14.55x

EPS Basic Excl Extra (Annual)$-2.14

P/FCF (TTM)4.92x

Receivables Turnover (TTM)1.39x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.97

Receivables Turnover (Annual)1.39x

ROI (TTM)-246.04%

P/S Ratio (TTM)27.30x

Pretax Margin (5Y Avg)-2441.11%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.83

Price vs S&P 500 (52W)-80.81%

Year-to-Date Return-32.09%

5-Day Price Return133.27%

EPS Normalized (Annual)$-2.14

ROA (5Y Avg)-83.64%

Net Profit Margin (Annual)-6925.17%

Month-to-Date Return163.77%

Cash Flow / Share (TTM)$-1.38

EBITD / Share (Annual)$-2.28

Operating Margin (Annual)-7907.77%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-130.65%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.97

P/TBV (Quarterly)10.22x

P/B Ratio (Annual)2.55x

Inventory Turnover (TTM)29.64x

Pretax Margin (TTM)-1547.28%

Book Value / Share (Annual)$0.52

Price vs S&P 500 (13W)-30.62%

Beta1.91x

Revenue / Share (TTM)$0.00

ROE (TTM)-246.04%

52-Week Low$0.28

vGradeC

gGradeF

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.28est. -0.29

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
SNGXSoligenix, Inc. Common Stock	C	F	D	$0.83
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Soligenix is a biopharmaceutical company developing therapeutics and vaccines for rare diseases and public health threats with unmet medical needs. Operating through Specialized BioTherapeutics and Public Health Solutions segments, the company generates primary revenues from Public Health Solutions, including RiVax (a ricin toxin vaccine candidate), SGX943 (for antibiotic-resistant and emerging infectious diseases), and vaccine research programs targeting Ebola, Marburg, and SARS-CoV-2.